Mixed first-quarter results from Regeneron

US biotech firm Regeneron Pharmaceuticals (Nasdaq: REGN) today reported first-quarter 2018 financials, showing mixed results, with total revenues of $1.51 billion (up 15%) missing consensus by 1% and Leerink estimates by 5%.

First quarter 2018 generally accepted accounting principles (GAAP) net income per diluted share increased by 93% to $4.16 and non-GAAP net income per diluted share increased 60% to $4.67 versus first quarter 2017, 67 beating consensus by 4% and missing Leerink’s estimate by 1%, said the latter’s analysts Geoffrey Porges.

The revenue weakness in the quarter was anticipated by investors based on collaboration partner Sanofi’s (Euronext: SAN) disclosure last week about the lower-than-anticipated Dupixent (dupilumab) sales.